QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cindy B. who wrote (76)	2/12/1997 6:55:00 PM
From: Donald Gravenor	of 1321

I don't think this indication is driving this stock. In patients with obstructing CA esophagus, the latest contraption is a metal tube which expands when placed in a stenosed esophagus (via endoscopy). It has replaced silastic tubes, which are expensive, and have a tendancy to get displaced. If you have a superficial esophageal CA, you are the luckiest person around, as almost everyone has deep invasion. Treating the surface mucosa won't make a difference. There is an article in today's Financial Post (Canada) which shows that the drug is now indicated for obstructed lung cancer, but again, this is a late stage, strictly palliative treatment. I think that the retinal drugs are driving this stock higher.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next